(Source: Alnylam Pharmaceuticals Inc) 07.25.2016 - Fitusiran Achieves Median Estimated Annualized Bleeding Rate of Zero in Patients without Inhibitors - - In Initial Low Dose Cohort of Patients with Inhibitors, Fitusiran Achieves Antithrombin Lowering, Increased Thrombin Generation, and Preliminary Evidence for Reduced Bleeding - - Fitusiran Administration Generally Well Tolerated in Hemophilia Patients with and without Inhibitors - - Company Updates Guidance for Phase 3, and Now Plans to Start Studies in Early 2017 - - Company has Rescheduled its Conference Call, which will Now Occur Today, Monday, July 25, at 1:00 pm ET - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc....
↧